Table 1.
Baseline characteristic of study population.
| Variables | Overall (N = 1491) |
Male (N = 888) |
Female (N = 603) |
p_value |
|---|---|---|---|---|
| Age (year) | 49.54 (12.20) | 47.32 (11.67) | 52.81 (12.25) | <0.001 |
| BMI (kg/m2) | 25.63 (3.46) | 25.95 (3.23) | 25.15 (3.71) | <0.001 |
| SBP (mm Hg) | 124.22 (15.72) | 125.15 (14.64) | 122.85 (17.12) | 0.005 |
| DBP (mm Hg) | 72.85 (10.09) | 73.55 (10.00) | 71.81 (10.14) | 0.001 |
| Chest pain (N,%) | 521 (34.9) | 283 (31.9) | 238 (39.5) | 0.003 |
| Syncope (N,%) | 306 (20.5) | 186 (20.9) | 120 (19.9) | 0.671 |
| Palpitation (N,%) | 403 (27.0) | 242 (27.3) | 161 (26.7) | 0.860 |
| Dizziness (N,%) | 283 (19.0) | 162 (18.2) | 121 (20.1) | 0.416 |
| AF (N,%) | 202 (13.5) | 136 (15.3) | 66 (10.9) | 0.019 |
| Diabetes (N,%) | 95 (6.4) | 58 (6.5) | 37 (6.1) | 0.842 |
| Hyperlipidemia (N,%) | 669 (44.9) | 401 (45.2) | 268 (44.4) | 0.827 |
| Hypertension (N,%) | 470 (31.5) | 272 (30.6) | 198 (32.8) | 0.399 |
| Cerebrovascular disease (N,%) | 52 (3.5) | 29 (3.3) | 23 (3.9) | 0.679 |
| Pulmonary hypertension (N,%) | 404 (27.1) | 177 (19.9) | 227 (37.6) | <0.001 |
| Smoking (N,%) | 562 (37.7) | 527 (59.3) | 35 (5.8) | <0.001 |
| FHCM (N,%) | 112 (7.5) | 65 (7.3) | 47 (7.8) | 0.809 |
| FSCD (N,%) | 48 (3.2) | 26 (2.9) | 22 (3.6) | 0.533 |
| Previous heart surgery (N,%) | 99 (6.6) | 68 (7.7) | 31 (5.1) | 0.07 |
| NYHA III/IV (N,%) | 1131 (75.9) | 647 (72.9) | 484 (80.3) | 0.001 |
| Coronary artery disease (N,%) | 209 (14.0) | 129 (14.5) | 80 (13.3) | 0.541 |
| Left atrial diameter (mm) | 44.90 (6.82) | 45.68 (7.06) | 43.75 (6.27) | <0.001 |
| IVST (mm) | 20.15 (6.76) | 20.53 (5.26) | 19.59 (8.48) | 0.009 |
| LVEDD (mm) | 42.84 (5.24) | 43.76 (5.03) | 41.48 (5.27) | <0.001 |
| EF(100 %) | 69.19 (5.83) | 69.27 (5.70) | 69.09 (6.01) | 0.555 |
| RVD (mm) | 21.35 (2.99) | 21.67 (2.77) | 20.87 (3.23) | <0.001 |
| MWT (mm) | 22.22 (4.82) | 22.81 (4.95) | 21.37 (4.48) | <0.001 |
| SAM (N, %) | 1425 (95.6) | 846 (95.3) | 579 (96.0) | 0.574 |
| LVOT gradient (mm Hg) | 83.21 (32.09) | 79.88 (30.39) | 88.12 (33.87) | <0.001 |
| Moderate or severe MR (N, %) | 788 (52.9) | 425 (47.9) | 363 (60.2) | <0.001 |
| Statin, (N, %) | 250 (16.8) | 145 (16.3) | 105 (17.4) | 0.632 |
| Hypoglycemic (N, %) | 87 (5.8) | 49 (5.5) | 38 (6.3) | 0.602 |
| β receptor Blockers (N, %) | 1424 (95.5) | 849 (95.6) | 575 (95.4) | 0.918 |
| Calcium channel blockers (N, %) | 477 (32.0) | 272 (30.6) | 205 (34.0) | 0.190 |
| ACEI (N, %) | 82 (5.5) | 45 (5.1) | 37 (6.1) | 0.440 |
| ARB (N, %) | 99 (6.6) | 60 (6.8) | 39 (6.5) | 0.909 |
BMI indicates body mass index; AF, atrial fibrillation; FHCM, family history of hypertrophic cardiomyopathy; FSCD, family history of sudden cardiac death; IVST, introventricular septal thickness; LVEDD, left ventricular end-diastolic diameter; EF, ejection fraction; RVD, right ventricular diameter; SAM, systolic anterior motion; LVOT, left ventricular outflow tract; MR, mitral regurgitation; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker.